MILWAUKEE, March 18, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Aldeyra (Nasdaq: ALD). The investigation results from inaccurate statements Aldeyra may have made regarding its financial statements, business operations and prospects.
Click here to join our investigation or to obtain additional information, or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.
The investigation focuses on whether Aldeyra disclosed problems in its clinical trials for reproxalap for dry eye disease.
We specialize in securities fraud and shareholder litigation. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Ademi LLP
Guri Ademi
3620 East Layton Ave.
Cudahy, WI 53110
Toll Free: (866) 264-3995
Fax: (414) 482-8001
www.ademilaw.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-claims-of-securities-fraud-against-aldeyra-therapeutics-inc-302717679.html
SOURCE Ademi LLP
